Figure 4From: Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpressionThese serial CT scans demonstrate the efficacy of re-treatment with everolimus 10 mg/d. The liver metastases remained stable during the period of re-treatment with everolimus for over 2 years.Back to article page